Abstract
The aim of the present study was to determine whether treatment with liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, would alter mammalian target of rapamycin complex 1 (mTORC1) signaling and/or α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor activity under dexamethasone-induced toxic conditions. Western blot analyses were performed to assess changes in mTORC1-mediated proteins, brain-derived neurotrophic factor (BDNF), and various synaptic proteins (PSD-95, synapsin I, and GluA1) in rat hippocampal cultures under toxic conditions induced by dexamethasone, which causes hippocampal cell death. Hippocampal dendritic outgrowth and spine formation were measured using immunostaining procedures. Dexamethasone significantly decreased the phosphorylation levels of mTORC1 as well as its downstream proteins. However, treatment with liraglutide prevented these reductions and significantly increased BDNF expression. The increase in BDNF expression was completely blocked by rapamycin and 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX). Liraglutide also recovered dexamethasone-induced decreases in the total length of hippocampal dendrites and reductions in spine density in a concentration-dependent manner. However, the positive effects of liraglutide on neural plasticity were abolished by the blockade of mTORC1 signaling and AMPA receptors. Furthermore, liraglutide significantly increased the expression levels of PSD-95, synapsin I, and GluA1, whereas rapamycin and NBQX blocked these effects. The present study demonstrated that liraglutide activated mTORC1 signaling and AMPA receptor activity as well as increased dendritic outgrowth, spine density, and synaptic proteins under toxic conditions in rat primary hippocampal neurons. These findings suggest that GLP-1 receptor (GLP-1R) activation by liraglutide may affect neuroplasticity through mTORC1 and AMPA receptors.
Introduction
Depressive disorder is a very common psychiatric illness that typically has a chronic course (Andrade et al., 2003). The lifetime prevalence of depressive disorder is approximately 17% in the United States (Andrade et al., 2003; Kessler et al., 2003). In addition to experiencing a depressed mood, patients with depressive disorder may exhibit compromised social functioning, decreased quality of life, and an elevated risk of medical illnesses (Brown et al., 2009; Dhar and Barton, 2016; Kupferberg et al., 2016). Thus, the burden of illness associated with depressive disorder necessitates genuinely novel treatment approaches (Millan et al., 2015). More than 50 years after the monoamine hypothesis of depression has been proposed, several monoamine-based antidepressants have been developed. It is now widely used as a pharmacological treatment for depression (Hillhouse and Porter, 2015). But, many difficulties are still associated with pharmacotherapies for depressive disorder (Lee et al., 2010; Popa-Velea et al., 2015). Thus, there is a need for innovative treatment strategies that utilize newly identified molecular mechanisms.
Novel agents that target molecular effector systems relevant to neuroplasticity and neurogenesis represent a promising research opportunity for psychiatry (Massart et al., 2012; Vialou et al., 2013; Pilar-Cuellar et al., 2014). In terms of neuroplastic mechanisms, much attention has been focused on plastic changes in neural connectivity that operate via the mammalian target of rapamycin complex 1 (mTORC1) pathway (Li et al., 2010; Duman et al., 2012). For example, Li et al. (2010) observed that the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine decreases immobility time in the forced swimming test (FST), activates mTORC1 signaling, and increases synaptic protein levels (PSD-95, synapsin I, and GluA1) in the prefrontal cortex of mice. Furthermore, Maeng et al. (2008) demonstrated that the activation of mTORC1 signaling by ketamine and the associated antidepressant behavioral responses require the activation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors. The activations of AMPA and neurotrophic receptors play important roles in the synthesis of synaptic proteins that support synaptic plasticity (Ignacio et al., 2016).
Glucagon-like peptide 1 (GLP-1) is an endogenous incretin hormone composed of 30 amino acids that exerts differential effects based on its synthesis site and release (Holst et al., 2011). When GLP-1 is released in response to fat and carbohydrates by small intestinal L-cells, the activation of the GLP-1 receptor (GLP-1R) stimulates glucose-dependent insulin secretion, the synthesis of insulin, β-cell proliferation, and the inhibition of β-cell apoptosis (Drucker, 2001; Zhou et al., 2015). In contrast, when GLP-1 is released in the brain, it functions as a neuropeptide (Holst et al., 2011). GLP-1Rs are widely expressed throughout the brain in rodents and humans in areas such as the caudate putamen, cerebral cortex, and hippocampus (Perry et al., 2002; Perry and Greig, 2004; Li M. et al., 2015). Accumulating evidence indicates that GLP-1 acts as a neuronal growth factor and it has been shown that GLP-1 enhances neurite outgrowth and protects against oxidative injury in PC12 and SK-N-SH human neuroblastoma cells (Li M. et al., 2015).
Liraglutide, which is a GLP-1R agonist, is approved by the U.S. Food and Drug Administration as an adjunct to diet and exercise and is aimed at improving weight loss and glycemic control in adults with type 2 diabetes (Gross, 2013). However, in addition to its anti-diabetic treatment effects, recent studies have shown that liraglutide may have neuroprotective effects and can modulate neuroplasticity as well as cognitive function. Liraglutide exerts neurotrophin-like activity at least in part via the MEK-ERK signaling pathway (Li M. et al., 2015) and its neuroprotective effects appear to operate via reductions in excessive levels of reactive oxygen species (ROS; Zhu et al., 2016). Liraglutide also decreases the hyperphosphorylation of tau and neurofilament proteins and improves learning and memory ability in mice (Xiong et al., 2013). Although several studies have suggested possible molecular mechanisms underlying the effects of liraglutide (O’Neill, 2013), no studies have investigated the neuroplastic effects of liraglutide and its association with mTORC1 signaling or AMPA receptors. Thus, the present study aimed to determine whether there is an association of the neuroplastic effects of liraglutide with the activations of mTORC1 signaling and AMPA receptors. For this study, we used a synthetic glucocorticoid dexamethasone as neurotoxic model for screening the neuroplastic effects of liraglutide. Excessive glucocorticoid levels in depression lead to hippocampal atrophy and disturbances of neuroplasticity (McEwen et al., 1992). Dexamethasone in neuronal cells was reported to reduce cell viability, cell proliferation, and neurite outgrowth (Obradovic et al., 2006; Leskiewicz et al., 2013). Thus, the effects of liraglutide on mTORC1 signaling, AMPA receptor activity, synaptic protein expression, neurite outgrowth, and synaptic density were investigated using rat primary hippocampal neurons under dexamethasone-induced toxic conditions.
Materials and Methods
Drugs and Reagents
Liraglutide and dexamethasone were purchased from GL Biochem Ltd. (Shanghai, China) and Sigma (St. Louis, MO, United States), respectively. The reagents used for the primary hippocampal cultures were purchased from Invitrogen (Carlsbad, CA, United States) and included dimethyl sulfoxide (DMSO), neurobasal medium, fetal bovine serum (FBS), horse serum (HS), B27 supplement, L-glutamine, penicillin-streptomycin, and trypsin. The antibodies used for the Western blot analyses were purchased from the following sources: anti-BDNF (sc-546), anti-synapsin I (sc-8295), anti-rabbit (sc-2004), and anti-goat (sc-2020) IgG-horseradish peroxide-conjugates from Santa Cruz Biotechnology (Santa Cruz, CA, United States); monoclonal anti-α-tubulin (T9026) and anti-mouse IgG peroxidase conjugates (A4416) from Sigma; anti-phospho-mTORC1 (Ser2448, #2971), anti-mTORC1 (#2972), anti-phospho-4E-BP-1 (Thr37/46, #2855), anti-4E-BP-1 (#9452), anti-phospho-p70S6K (Thr389, #9205), and anti-p70S6K (#9202) from Cell Signaling Technology (Beverly, MA, United States); anti-PSD-95 (AB9634) from Millipore (Temecula, CA, United States); and anti-GluA1 (ab109450) from Abcam (Cambridge, United Kingdom).
The antibodies used for immunostaining were purchased from the following sources: anti-microtubule-associated protein 2 (MAP2; MAB3418) from Millipore; Alexa Fluor® 568 goat anti-mouse IgG (A11031) and Hoechst 33258 (H21491) from Invitrogen; and Alexa Fluor® 488 Phalloidin from Molecular Probes (Eugene, OR, United States). Specific kinase inhibitors were purchased from the following sources: PI3K inhibitor LY294002 from Cell Signaling Technology; MEK inhibitor PD98059 and mTORC1 inhibitor rapamycin from Calbiochem (San Diego, CA, United States); and the AMPA receptor inhibitor 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f] quinoxaline-7-sulfonamide (NBQX) from Tocris Bioscience (Ballwin, MO, United States).
Primary Hippocampal Cell Cultures
Pregnant Sprague-Dawley rats were obtained from Orient Bio (Seongnam, South Korea) and all experimental procedures were approved by the Inje Medical College Committee for Animal Experimentation and the Institutional Animal Laboratory Review Board (Approval no. 2015-027).
Hippocampal cell cultures were prepared from the hippocampi of fetuses at embryonic day 17 in a manner similar to that reported by Kaech and Banker (2006). Briefly, the hippocampi were carefully removed and dispersed in neurobasal medium containing 0.03% trypsin for digestion at 37°C (5% CO2) for 20 min. Next, the cells were suspended in a medium including 1% FBS, 1% HS, 2% serum-free growth medium B27, 0.25% L-glutamine, and 50 U/ml penicillin-streptomycin; this was the control condition. For the Western blot analyses, the cells were plated on 6-well dishes coated with poly-L-lysine at a density of 2 × 105 cells per dish. For the neurite and spine assays, the cells were plated on 12-well dishes at a density of 2 × 104 or 5 × 103 cells per dish. They were grown under the control condition for either 7 days (for the neurite and spine assays) or 10 days (for Western blots). After incubation for 7 or 10 days, the cells were treated with liraglutide in the presence or absence of 500 μM dexamethasone for either 4 days (for the Western blots) or 5 days (for the neurite and spine density assays) before being harvested for further analysis. In a preliminary experiment performed by our research group, exposure to 500 μM dexamethasone caused a significant reduction in hippocampal cell viability (approximately 22% decrease; Supplementary Figure 1).
Drug Treatment
Liraglutide (1 μM) was completely dissolved in distilled water and then diluted to various concentrations also using distilled water prior to use. Dexamethasone (50 mM) was dissolved in DMSO (Amresco, OH, United States) and then diluted to a final concentration of 500 μM using 1% DMSO prior to use. For the Western blot analyses, the cells were cultured for 4 days with liraglutide (10 or 100 nM) and, for the neurite and spine density assays, the cells were cultured for 5 days with liraglutide (100 nM) in the presence or absence of dexamethasone. The range of liraglutide concentration used in the present study was based on studies showing that liraglutide exerts neuroprotective effects in various cell cultures (Miao et al., 2013; Sharma et al., 2014; Li Y. et al., 2015).
Western Blot Analysis
The Western blot experiments were performed as previously described (Seo et al., 2014). Briefly, the hippocampal cells were homogenized in ice-cold lysis buffer (20 mM Tris–HCl, 137 mM NaCl, 10% glycerol, 1% NonidetTM P-40, 0.1% sodium dodecyl sulfate [SDS], 0.5% sodium deoxycholate, and 2 mM ethylenediaminetetraacetic acid [EDTA]) and one complete protease inhibitor tablet (Roche; Laval, QC, Canada). The lysates were centrifuged (1000 × g, 15 min, 4°C) and the samples were stored at -80°C until use. Immunoblotting was performed with one of the primary antibodies (anti-phospho-mTORC1, anti-mTORC1, anti-phospho-4E-BP-1, anti-4E-BP-1, anti-phospho-p70S6K, anti-p70S6K, anti-BDNF, anti-PSD-95, anti-synapsin I, or anti-GluA1 [1:1000] and anti-α-tubulin [1:2000]) in Tris-buffered saline with Tween-20 (TBS-T) at 4°C overnight and then the membranes were washed three times in TBS-T for 10 min. The membranes were then incubated for 1 hr in TBS-T containing a horseradish peroxidase-conjugated secondary antibody (goat-anti-rabbit IgG for anti-phospho-mTORC1, anti-mTORC1, anti-phospho-4E-BP-1, anti-4E-BP-1, anti-phospho-p70S6K, anti-BDNF, anti-p70S6K, anti-phospho-eIF4B, anti-eIF4B, anti-phospho-S6, anti-S6, anti-BDNF, anti-PSD-95, or anti-GluA1 [1:2000]; donkey-anti-goat IgG for anti-synapsin I [1:2000]; or anti-mouse IgG for anti-α-tubulin [1:10,000]) at room temperature. The Western blot analyses were repeated two times per group for each of the two independent cultures.
Neurite Assay
Dendrites were visualized via immunostaining using a MAP-2 antibody, which is a dendritic marker, as previously described (Park et al., 2016). To analyze total dendritic length, five fields were randomly selected from each group and two independent cultures were performed. All neurons in a given field were counted, including both basal and apical dendrites, and dendritic length was determined to be the distance between the edge of the cell body and the tip of the growth cone. Total dendritic length was obtained by summing the lengths of all dendrites from a single neuron and then averaging this measure in each group using MetaMorph (Molecular Devices, Downingtown, PA, United States), an automated image-analysis program (Klimaschewski et al., 2002). At least 400 cells were analyzed in 10 fields by a researcher blind to the groups.
Spine Density Assay
Spines were stained with phalloidin as previously described (Park et al., 2016). To analyze spine density, spines, and filopodia were differentiated by shape and length such that spines were defined as less than 3 μm long with a rounder or mushroom shape while filopodia were defined as between 3 and 10 μm long with a narrower shape. Ten neurons were randomly selected from each group and two independent cultures were performed. Using 12–20 neurons per group, two dendritic segments per neuron (50 μm) were analyzed (23–40 dendritic segments per group) by a researcher blind to the groups. To represent average spine density in a 10-μm dendrite, the spine density of a 50-μm dendritic segment was divided by 5.
Statistical Analysis
All statistical analyses were performed using GraphPad Prism software (ver. 7.03; GraphPad Software, La Jolla, CA, United States). Changes in the levels of mTORC1-mediated proteins were analyzed by one-way analysis of variance (ANOVA) followed by post hoc Tukey’s multiple comparisons. Two-way ANOVA was used to assess the main effect of liraglutide or the inhibitor and the interaction between liraglutide and the inhibitor; when warranted, Tukey’s multiple comparisons were carried out. P-values <0.05 were considered to indicate statistical significance.
Results
Effects of Liraglutide on mTORC1, 4E-BP-1, and p70SK Levels in Rat Hippocampal Cells Under the Dexamethasone-Induced Toxic Condition
Dexamethasone treatment significantly reduced the phosphorylation levels of mTORC1, 4E-BP-1, and p70S6K (phospho-Ser2448-mTORC1 levels: 40% of control, p < 0.001; phospho-Thr37/46-4E-BP-1 levels: 30% of control, p < 0.001; phospho-Thr389-p70S6K levels: 28% of control, p < 0.001, Figures 1A–C). In the dexamethasone condition, liraglutide (100 nM) significantly prevented reductions in the phosphorylation levels of mTORC1, 4E-BP-1, and p70S6K (phospho-Ser2448-mTORC1 levels: ANOVA, F[3,12] = 42.310, p < 0.001; post hoc, p = 0.001, Figure 1A; phospho-Thr37/46-4E-BP-1 levels: ANOVA, F[3,12] = 49.800, p < 0.001; post hoc, p = 0.001, Figure 1B; phospho-Thr389-p70SK levels: ANOVA, F[3,12] = 26.630, p < 0.001; post hoc, p < 0.001, Figure 1C). In addition, liraglutide prevented the dexamethasone-induced decrease in the phosphorylation levels of eIF4B and S6 (Supplementary Figures 2A,B).
FIGURE 1
Activations of mTORC1 Signaling and AMPA Receptors Were Necessary for the Effects of Liraglutide on BDNF Expression in Rat Hippocampal Cells Under Dexamethasone-Induced Toxic Conditions
The present study further examined whether the activations of mTORC1 signaling and AMPA receptors would contribute to the regulation of BDNF expression induced by liraglutide following the administration of dexamethasone. Two-way ANOVA revealed significant effects of liraglutide (F[1,12] = 10.130, p = 0.008), rapamycin (F[1,12] = 11.080, p = 0.006), and the liraglutide × rapamycin interaction (F[1,12] = 8.279, p = 0.010) as well as liraglutide (F[1,12] = 13.100, p = 0.004), NBQX (F[1,12] = 7.774, p = 0.020), and the liraglutide × NBQX interaction (F[1,12] = 10.140, p = 0.008) for BDNF expression. Post hoc analyses revealed that liraglutide significantly increased BDNF expression (p = 0.001) and that this increase was blocked by rapamycin (p = 0.002) and NBQX (p < 0.010; Figure 2).
FIGURE 2
Effects of Liraglutide on Dendritic Outgrowth and Spine Formation in Rat Hippocampal Cells Under Dexamethasone-Induced Toxic Conditions
Hippocampal cells were incubated with liraglutide (10 or 100 nM) under either control or dexamethasone (500 μM) condition for 5 days. They were then photographed and assessed to quantify total dendritic length (Figure 3A) and spine density (Figure 3B) following treatment with liraglutide. Liraglutide did not affect total dendritic length or spine density in hippocampal cells under the control condition (Supplementary Table 1). In the absence of dexamethasone, control cells exhibited modest dendritic differentiation and an average dendritic length of approximately 50 μm (Figure 3A). On the other hand, dexamethasone-treated cells exhibited a decreased total dendritic length compared to control cells (dexamethasone-treated cells vs. control cells: 40 μm vs. 50 μm, p = 0.020, Figure 3A) but this reduction was prevented by liraglutide in a concentration-dependent manner (ANOVA; F[3,1596] = 12.860, p < 0.001; 10 nM = 53 μm, p < 0.001; 100 nM = 61 μm, p < 0.001, Figure 3A).
FIGURE 3
The changes in spine density were similar to those observed for total dendritic length. Spine density was significantly reduced in dexamethasone-treated cells compared to that in control cells (dexamethasone-treated cells vs. control cells: 0.6 vs. 1.2, p < 0.001, Figure 3B), but liraglutide significantly prevented the reduction in dendritic spine density in a concentration-dependent manner under the dexamethasone condition (ANOVA; F[3,156] = 17.000, p < 0.001; 10 nM = 0.9, p = 0.030; 100 nM = 1.4, p < 0.001, Figure 3B).
Effects of mTORC1 and AMPA Receptor Inhibitors on Liraglutide-Induced Increases in Dendritic Outgrowth and Spine Formation
To investigate the roles that mTORC1 signaling and AMPA receptors play in the enhancement of liraglutide-induced dendritic outgrowth and spine formation, hippocampal cells were pretreated with rapamycin or NBQX under the dexamethasone condition. Two-way ANOVA revealed significant differences for rapamycin (F[1,1596] = 23.380, p < 0.001), liraglutide (F[1,1596] = 183.800, p < 0.001), and the rapamycin × liraglutide interaction (F[1,1596] = 57.790, p < 0.001) as well as NBQX (F[1,1596] = 50.610, p < 0.001), liraglutide (F[1,1596] = 192.300, p < 0.001), and the NBQX × liraglutide interaction (F[1,1596] = 86.210, p < 0.001) for total dendritic length. More specifically, rapamycin and NBQX inhibited the enhancement of total dendritic length induced by liraglutide (liraglutide vs. rapamycin + liraglutide: 64 μm vs. 55 μm, p < 0.001; liraglutide vs. NBQX + liraglutide: 64 μm vs. 53 μm, p < 0.001; Figure 4A).
FIGURE 4
Statistical analyses of spine density revealed significant effects of rapamycin (F[1,101] = 29.840, p < 0.001), liraglutide (F[1,101] = 78.260, p < 0.001), and the rapamycin × liraglutide interaction (F[1,101] = 26.680, p < 0.001) as well as NBQX (F[1,103] = 33.470, p < 0.001), liraglutide (F[1,103] = 34.370, p < 0.001), and the NBQX × liraglutide interaction (F[1,103] = 75.040, p < 0.001). Post hoc analyses showed that rapamycin and NBQX inhibited the liraglutide-induced enhancement of spine density (liraglutide vs. rapamycin + liraglutide: 3.0 vs. 1.6, p < 0.001; liraglutide vs. NBQX + liraglutide: 3.0 vs. 1.1, p < 0.001, Figure 4B).
Activations of mTORC1 Signaling and AMPA Receptors Necessary for the Effects of Liraglutide on Synaptic Protein Expression in Rat Hippocampal Cells Under the Dexamethasone-Induced Toxic Condition
Whether liraglutide would similarly enhance the expression of various synaptic proteins, including PSD-95, synapsin I, and GluA1, through the activation of mTORC1 signaling and AMPA receptors was investigated in hippocampal cells under the dexamethasone condition.
Two-way ANOVA revealed significant effects of liraglutide (F[1,12] = 26.750, p < 0.001), rapamycin (F[1,12] = 10.370, p = 0.007), and their interaction (F[1,12] = 9.630, p = 0.009) as well as main effects of liraglutide (F[1,12] = 17.330, p = 0.001), NBQX (F[1,12] = 5.381, p = 0.040), and their interaction (F[1,12] = 5.186, p = 0.040) for PSD-95 expression; significant effects of liraglutide (F[1,12] = 16.750, p = 0.008), rapamycin (F[1,12] = 10.290, p = 0.001), and their interaction (F[1,12] = 15.810, p = 0.002) as well as significant effects of liraglutide (F[1,12] = 5.710, p = 0.030), NBQX (F[1,12] = 15.630, p = 0.002), and their interaction (F[1,12] = 5.349, p = 0.040) for synapsin I expression; and significant effects of liraglutide (F[1,12] = 35.800, p < 0.001), rapamycin (F[1,12] = 35.800, p < 0.001), and their interaction (F[1,12] = 22.310, p < 0.001), as well as significant effects of liraglutide (F[1,12] = 26.350, p < 0.001), NBQX (F[1,12] = 31.440, p < 0.001), and their interaction (F[1,12] = 26.350, p < 0.001) for GluA1 expression. Liraglutide significantly increased the expression of PSD-95 (156% of control, p = 0.020; Figure 5A), synapsin I (174% of control, p = 0.001; Figure 5B), and GluA1 (160% of control, p < 0.001; Figure 5C). However, the positive effects of liraglutide were blocked by rapamycin (p = 0.002 for PSD-95, Figure 5A; p < 0.001 for synapsin I, Figure 5B; and p < 0.001 for GluA1, Figure 5C) and NBQX (p = 0.001 for PSD-95, Figure 5A; p = 0.020 for synapsin I, Figure 5B; and p < 0.001 for GluA1, Figure 5C).
FIGURE 5
Discussion
The present study demonstrated that liraglutide influenced mTORC1 signaling and AMPA receptor activities and was associated with changes in the expression of synaptic proteins, neurite outgrowth, and synaptic density in rat primary hippocampal neurons treated with toxic levels of dexamethasone.
Liraglutide is a long-acting human GLP-1 analog that has a 97% amino acid sequence identity with human GLP-1 (Miao et al., 2013). As a result, liraglutide is a potent antidiabetic agent that is protective against pancreatic β-cell apoptosis in vitro and increases pancreatic β-cell mass in vivo (Rolin et al., 2002; Bregenholt et al., 2005). In addition to these reported effects, liraglutide may also be neuroprotective and alter neuroplasticity in the brain (Holst et al., 2011; Hunter and Holscher, 2012; Xiong et al., 2013; Zhu et al., 2016). In preclinical studies, GLP-1 and its longer-lasting analogs decrease apoptosis, protect neurons from oxidative stress and inflammation, induce neurite outgrowth, protect neural plasticity, and enhance memory formation in the brains of animals in mouse models of Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative diseases (Holscher, 2010, 2012; Xiong et al., 2013; Liu et al., 2015). In a study of GLP-1R knockout mice, GLP-1R-deficient mice exhibited a phenotype characterized by learning deficits that were restored by hippocampal Glp1r transfer (During et al., 2003). Additionally, GLP-1R affects neurite outgrowth and neuroplasticity. In a separate study, Li M. et al. (2015) found that liraglutide induces neurite outgrowth in C57BL/6 mouse primary cortical neurons and that this effect is blocked by the MEK-ERK inhibitor U0126. Hunter and Holscher (2012) reported that peripherally administered liraglutide and lixisenatide cross the blood–brain barrier in C57BL/6 mice where they enhance cyclic adenosine monophosphate (cAMP) levels and increase neurogenesis. Taken together, these results provide the basis for speculations that liraglutide may have neuroplastic effects.
However, the underlying mechanisms by which GLP-1 and GLP-1 analogs induce neuroplastic effects via mTORC1 signaling remained unclear. Most studies have examined the effects of GLP-1 or GLP-1 analogs on mTORC1 signaling and its protective effects using pancreatic β-cells. Miao et al. (2013) found that liraglutide increases INS-1 cells and activates mTOR as well as its downstream effectors, including 70-kDa ribosomal protein S6 kinase and eIF4E-binding proteins. These authors also observed that liraglutide prevents pancreatic β-cell glucolipotoxicity via mTOR and that the actions of liraglutide are attenuated by AICAR, which is an AMPK activator, and rapamycin, which is an mTOR inhibitor (Miao et al., 2013).
The present study investigated rat primary hippocampal neurons and found that liraglutide promoted mTORC1 signaling activities under dexamethasone-induced toxic conditions. Liraglutide increased the phosphorylation of mTORC1 downstream effectors (p70S6K and 4E-BP-1) as well as the levels of BDNF and various synaptic proteins (PSD-95, Synapsin I, and GluA1) and enhanced synaptic density and neurite outgrowth. In addition to its effects on mTORC1 signaling activation, recent studies have shown that ketamine rapidly increases glutamate release and stimulates AMPA receptors, mTORC1 signaling, and synaptogenesis through the increased release of BDNF and enhanced AKT activation (Duman et al., 2012). Subsequently, released BDNF stimulates the syntheses of synaptic proteins, including PSD-95, synapsin I, and GluA1, in the prefrontal cortex of mice and contributes to the rapid antidepressant effects of ketamine (Duman et al., 2012; Dwyer and Duman, 2013; Abdallah et al., 2015). It has been proposed that PSD-95 plays an essential role in the maintenance and regulation of synaptic AMPA receptor function and AMPA receptor-dependent synaptic plasticity (Han and Kim, 2008). Increased levels of PSD-95 may be due to the increased number and size of dendritic spines and/or increases in the total number of synapses (Xu, 2011). Synapsin I is a modulator of neuronal development such that higher levels of synapsin I accelerate the development of synapses (Valtorta et al., 2011). GluA1 is a subunit of the AMPA receptor and is found in synapses where it enhances synaptic transmission (Santos et al., 2009). In the present study, liraglutide increased the expression of BDNF, PSD-95, synapsin I, and GluA1, whereas rapamycin and NBQX blocked the expression of each of these. In other studies, To date, no reports of studies investigating the activation of AMPA receptors on hippocampal neurons by liraglutide have been published. The present study is the first to report the effects of liraglutide on the activation of AMPA receptors in rat primary hippocampal neurons.
Chronic stress may cause depressive behavior by decreasing brain volume and reducing synaptic connections (Duman and Aghajanian, 2012). The activation of mTORC1 induces dendritic outgrowth but the induction of dendritic outgrowth is blocked by rapamycin (Park et al., 2014; Seo et al., 2016). Similarly, the present study demonstrated that liraglutide reversed decreases in neurite outgrowth in the dexamethasone-induced toxic condition and that the effects of liraglutide were blocked by rapamycin administration. Additionally, the increase in neurite outgrowth induced by liraglutide was blocked when NBQX and rapamycin were administered. Monnerie and Le Roux (2006) reported that kainate-induced dendritic outgrowth in mouse cortical neurons is blocked by NBQX; therefore, it can be postulated that the activations of mTORC1 signaling and AMPA receptors by liraglutide may promote neurite outgrowth. The effects of liraglutide on synaptic density were also observed in the present study. Liraglutide prevented reductions in synaptic density in the dexamethasone-induced toxic condition, but this effect was blocked by rapamycin and NBQX. These results suggest that liraglutide-induced changes in neurite outgrowth and synaptic density may occur via the activations of mTORC1 signaling and AMPA receptors.
In the present study, there are several limitations to this study that should be noted. First, it remains unclear whether the concentration of liraglutide used in the present study can be used in in vivo environments, particularly in humans. Therefore, it will be necessary to confirm the effects of liraglutide on mTORC1 signaling and AMPA receptors in further experiments using animal models. Second, AMPA receptor activity was assessed using the administration of NBQX. To measure the activity of the AMPA receptor more accurately, measurements of the AMPA-excitatory synaptic current should be obtained following the administration of liraglutide (Shinohara, 2012). Third, only 100 nM rapamycin and 10 nM NBQX doses were used in the study and future studies with additional concentrations of these drugs will be necessary.
The present study was the first to investigate how liraglutide affects neuroplasticity via mTORC1 signaling and AMPA receptor activation. In this study, liraglutide activated mTORC1 signaling and AMPA receptors, increased the expression of BDNF and selected synaptic proteins, and enhanced neurite outgrowth and synaptic density under toxic conditions (Figure 6). Additionally, these liraglutide-induced changes were blocked by the mTORC1 inhibitor rapamycin and the AMPA receptor antagonist NBQX. These results indicate that liraglutide enacts neuroplastic regulation via mTORC1 signaling and AMPA receptor activation. Thus, it is possible that the activation of mTORC1 signaling and AMPA receptors may be a potential target for the modification of neural plasticity and the development of novel antidepressant drugs.
FIGURE 6
Statements
Author contributions
JL, SP, and RSM designed the study. MS and AC performed the experiments of this study. MS and SP wrote the protocol. SP and MS undertook the statistical analysis. RSM, RBM, YL, and J-HL contributed the methods and analysis tools. JL and SP wrote the first draft of the manuscript. All authors contributed to the approval of the final manuscript.
Funding
This work was supported by the 2018 Inje University research grant.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnins.2018.00756/full#supplementary-material
References
1
AbdallahC. G.SanacoraG.DumanR. S.KrystalJ. H. (2015). Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.Annu. Rev. Med.66509–523. 10.1146/annurev-med-053013-062946
2
AndradeL.Caraveo-AnduagaJ. J.BerglundP.BijlR. V.De GraafR.VolleberghW.et al (2003). The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys.Int. J. Methods Psychiatr. Res.123–21. 10.1002/mpr.138
3
BregenholtS.MoldrupA.BlumeN.KarlsenA. E.Nissen FriedrichsenB.TornhaveD.et al (2005). The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro.Biochem. Biophys. Res. Commun.330577–584. 10.1016/j.bbrc.2005.03.013
4
BrownA. D.BartonD. A.LambertG. W. (2009). Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment.CNS Drugs23583–602. 10.2165/00023210-200923070-00004
5
DharA. K.BartonD. A. (2016). Depressive disorder and the link with Cardiovascular disease.Front. Psychiatry7:33. 10.3389/fpsyt.2016.00033
6
DruckerD. J. (2001). Minireview: the glucagon-like peptides.Endocrinology142521–527. 10.1210/endo.142.2.7983
7
DumanR. S.AghajanianG. K. (2012). Synaptic dysfunction in depression: potential therapeutic targets.Science33868–72. 10.1126/science.1222939
8
DumanR. S.LiN.LiuR. J.DuricV.AghajanianG. (2012). Signaling pathways underlying the rapid antidepressant actions of ketamine.Neuropharmacology6235–41. 10.1016/j.neuropharm.2011.08.044
9
DuringM. J.CaoL.ZuzgaD. S.FrancisJ. S.FitzsimonsH. L.JiaoX.et al (2003). Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.Nat. Med.91173–1179. 10.1038/nm919
10
DwyerJ. M.DumanR. S. (2013). Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants.Biol. Psychiatry731189–1198. 10.1016/j.biopsych.2012.11.011
11
GrossB. (2013). Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.J. Pharm. Pract.26144–150. 10.1177/0897190012465985
12
HanK.KimE. (2008). Synaptic adhesion molecules and PSD-95.Prog. Neurobiol.84263–283. 10.1016/j.pneurobio.2007.10.011
13
HillhouseT. M.PorterJ. H. (2015). A brief history of the development of antidepressant drugs: from monoamines to glutamate.Exp. Clin. Psychopharmacol.231–21. 10.1037/a0038550
14
HolscherC. (2010). The role of GLP-1 in neuronal activity and neurodegeneration.Vitam. Horm.84331–354. 10.1016/B978-0-12-381517-0.00013-8
15
HolscherC. (2012). Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.CNS Drugs26871–882. 10.2165/11635890-000000000-00000
16
HolstJ. J.BurcelinR.NathansonE. (2011). Neuroprotective properties of GLP-1: theoretical and practical applications.Curr. Med. Res. Opin.27547–558. 10.1185/03007995.2010.549466
17
HunterK.HolscherC. (2012). Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.BMC Neurosci.13:33. 10.1186/1471-2202-13-33
18
IgnacioZ. M.ReusG. Z.ArentC. O.AbelairaH. M.PitcherM. R.QuevedoJ. (2016). New perspectives on the involvement of mTOR in depressive disorder as well as in the action of antidepressant drugs.Br. J. Clin. Pharmacol.821280–1290. 10.1111/bcp.12845
19
KaechS.BankerG. (2006). Culturing hippocampal neurons.Nat. Protoc.12406–2415. 10.1038/nprot.2006.356
20
KesslerR. C.BerglundP.DemlerO.JinR.KoretzD.MerikangasK. R.et al (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).JAMA2893095–3105. 10.1001/jama.289.23.3095
21
KlimaschewskiL.NindlW.PimplM.WaltingerP.PfallerK. (2002). Biolistic transfection and morphological analysis of cultured sympathetic neurons.J. Neurosci. Methods11363–71. 10.1016/S0165-0270(01)00473-3
22
KupferbergA.BicksL.HaslerG. (2016). Social functioning in major depressive disorder.Neurosci. Biobehav. Rev.69313–332. 10.1016/j.neubiorev.2016.07.002
23
LeeS.JeongJ.KwakY.ParkS. K. (2010). Depressive disorder research: where are we now?Mol. Brain3:8. 10.1186/1756-6606-3-8
24
LeskiewiczM.JantasD.RegulskaM.KaczanowskaJ.Basta-KaimA.BudziszewskaB.et al (2013). Antidepressants attenuate the dexamethasone-induced decrease in viability and proliferation of human neuroblastoma SH-SY5Y cells: a involvement of extracellular regulated kinase (ERK1/2).Neurochem. Int.63354–362. 10.1016/j.neuint.2013.07.007
25
LiM.LiS.LiY. (2015). Liraglutide promotes cortical neurite outgrowth via the MEK-ERK pathway.Cell. Mol. Neurobiol.35987–993. 10.1007/s10571-015-0193-7
26
LiY.BaderM.TamargoI.RubovitchV.TweedieD.PickC. G.et al (2015). Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice.J. Neurochem.1351203–1217. 10.1111/jnc.13169
27
LiN.LeeB.LiuR. J.BanasrM.DwyerJ. M.IwataM.et al (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.Science329959–964. 10.1126/science.1190287
28
LiuW.JalewaJ.SharmaM.LiG.LiL.HolscherC. (2015). Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease.Neuroscience30342–50. 10.1016/j.neuroscience.2015.06.054
29
MaengS.ZarateC. A.Jr.DuJ.SchloesserR. J.McCammonJ.ChenG.et al (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.Biol. Psychiatry63349–352. 10.1016/j.biopsych.2007.05.028
30
MassartR.MongeauR.LanfumeyL. (2012). Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression.Philos. Trans. R. Soc. Lond. B Biol. Sci.3672485–2494. 10.1098/rstb.2012.0212
31
McEwenB. S.GouldE. A.SakaiR. R. (1992). The vulnerability of the hippocampus to protective and destructive effects of glucocorticoids in relation to stress.Br. J. Psychiatry Suppl.16018–23. 10.1192/S0007125000296645
32
MiaoX. Y.GuZ. Y.LiuP.HuY.LiL.GongY. P.et al (2013). The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway.Peptides3971–79. 10.1016/j.peptides.2012.10.006
33
MillanM. J.GoodwinG. M.Meyer-LindenbergA.Ove OgrenS. (2015). Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders.Eur. Neuropsychopharmacol.25599–656. 10.1016/j.euroneuro.2015.01.016
34
MonnerieH.Le RouxP. D. (2006). Glutamate receptor agonist kainate enhances primary dendrite number and length from immature mouse cortical neurons in vitro.J. Neurosci. Res.83944–956. 10.1002/jnr.20805
35
O’ NeillC. (2013). PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer’s disease.Exp. Gerontol.48647–653. 10.1016/j.exger.2013.02.025
36
ObradovicD.GronemeyerH.LutzB.ReinT. (2006). Cross-talk of vitamin D and glucocorticoids in hippocampal cells.J. Neurochem.96500–509. 10.1111/j.1471-4159.2005.03579.x
37
ParkS. W.LeeJ. G.SeoM. K.LeeC. H.ChoH. Y.LeeB. J.et al (2014). Differential effects of antidepressant drugs on mTOR signalling in rat hippocampal neurons.Int. J. Neuropsychopharmacol.171831–1846. 10.1017/S1461145714000534
38
ParkS. W.Nhu leH.ChoH. Y.SeoM. K.LeeC. H.LyN. N.et al (2016). p11 mediates the BDNF-protective effects in dendritic outgrowth and spine formation in B27-deprived primary hippocampal cells.J. Affect. Disord.1961–10. 10.1016/j.jad.2016.02.010
39
PerryT.HaugheyN. J.MattsonM. P.EganJ. M.GreigN. H. (2002). Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.J. Pharmacol. Exp. Ther.302881–888. 10.1124/jpet.102.037481
40
PerryT. A.GreigN. H. (2004). A new Alzheimer’s disease interventive strategy: GLP-1.Curr. Drug Targets5565–571. 10.2174/1389450043345245
41
Pilar-CuellarF.VidalR.DiazA.CastroE.dos AnjosS.VargasV.et al (2014). Signaling pathways involved in antidepressant-induced cell proliferation and synaptic plasticity.Curr. Pharm. Des.203776–3794. 10.2174/13816128113196660736
42
Popa-VeleaO.GheorgheI. R.TruǎescuC. I.PurcãreaV. L. (2015). Current challenges and pitfalls in the pharmacological treatment of depression.J. Med. Life8181–186.
43
RolinB.LarsenM. O.GotfredsenC. F.DeaconC. F.CarrR. D.WilkenM.et al (2002). The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.Am. J. Physiol. Endocrinol. Metab.283E745–E752. 10.1152/ajpendo.00030.2002
44
SantosS. D.CarvalhoA. L.CaldeiraM. V.DuarteC. B. (2009). Regulation of AMPA receptors and synaptic plasticity.Neuroscience158105–125. 10.1016/j.neuroscience.2008.02.037
45
SeoM. K.LeeC. H.ChoH. Y.LeeJ. G.LeeB. J.KimJ. E.et al (2014). Effects of antidepressant drugs on synaptic protein levels and dendritic outgrowth in hippocampal neuronal cultures.Neuropharmacology79222–233. 10.1016/j.neuropharm.2013.11.019
46
SeoM. K.McIntyreR. S.ChoH. Y.LeeC. H.ParkS. W.MansurR. B.et al (2016). Tianeptine induces mTORC1 activation in rat hippocampal neurons under toxic conditions.Psychopharmacology2332617–2627. 10.1007/s00213-016-4309-7
47
SharmaM. K.JalewaJ.HölscherC. (2014). Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress.J. Neurochem.128459–471. 10.1111/jnc.12469
48
ShinoharaY. (2012). Quantification of postsynaptic density proteins: glutamate receptor subunits and scaffolding proteins.Hippocampus22942–953. 10.1002/hipo.20950
49
ValtortaF.PozziD.BenfenatiF.FornasieroE. F. (2011). The synapsins: multitask modulators of neuronal development.Semin. Cell Dev. Biol.22378–386. 10.1016/j.semcdb.2011.07.008
50
VialouV.FengJ.RobisonA. J.NestlerE. J. (2013). Epigenetic mechanisms of depression and antidepressant action.Annu. Rev. Pharmacol. Toxicol.5359–87. 10.1146/annurev-pharmtox-010611-134540
51
XiongH.ZhengC.WangJ.SongJ.ZhaoG.ShenH.et al (2013). The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice.J. Alzheimers Dis.37623–635. 10.3233/JAD-130584
52
XuW. (2011). PSD-95-like membrane associated guanylate kinases (PSD-MAGUKs) and synaptic plasticity.Curr. Opin. Neurobiol.21306–312. 10.1016/j.conb.2011.03.001
53
ZhouJ.WuJ.ZhengF.JinM.LiH. (2015). Glucagon-like peptide-1 analog-mediated protection against cholesterol-induced apoptosis via mammalian target of rapamycin activation in pancreatic betaTC-6 cells -1mTORbetaTC-6.J. Diabetes7231–239. 10.1111/1753-0407.12177
54
ZhuH.ZhangY.ShiZ.LuD.LiT.DingY.et al (2016). The neuroprotection of liraglutide against ischaemia-induced apoptosis through the activation of the PI3K/AKT and MAPK pathways.Sci. Rep.6:26859. 10.1038/srep26859
Summary
Keywords
mammalian target of rapamycin complex 1 signaling, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor, glucagon-like peptide 1 receptor, liraglutide, neuroplasticity, toxic condition
Citation
Park SW, Mansur RB, Lee Y, Lee J-H, Seo MK, Choi AJ, McIntyre RS and Lee JG (2018) Liraglutide Activates mTORC1 Signaling and AMPA Receptors in Rat Hippocampal Neurons Under Toxic Conditions. Front. Neurosci. 12:756. doi: 10.3389/fnins.2018.00756
Received
01 August 2018
Accepted
01 October 2018
Published
23 October 2018
Volume
12 - 2018
Edited by
Hector J. Caruncho, University of Victoria, Canada
Reviewed by
Patrizia Longone, Fondazione Santa Lucia (IRCCS), Italy; Min-Yu Sun, Washington University in St. Louis, United States
Updates
Copyright
© 2018 Park, Mansur, Lee, Lee, Seo, Choi, McIntyre and Lee.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Roger S. McIntyre, Roger.McIntyre@uhn.ca Jung Goo Lee, iybihwc@naver.com
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.